Clopidogrel and aspirin
This article was originally published in The Tan Sheet
Bristol-Myers Squibb/Sanofi-Synthelabo's Plavix antiplatelet agent has additional benefits when combined with aspirin in patients with acute coronary syndromes, researchers report in Aug. 16 NEJM. Salim Yusuf, PhD, McMaster University, et al., report death from cardiovascular causes, nonfatal MI or stroke occurred in 9.3% of patients taking clopidogrel and aspirin, compared with 11.4% death rate in patients taking placebo and aspirin. Although major bleeding was significantly more common in clopidogrel group (3.7% vs. 2.7% in placebo arm), Yusuf et al. say excess risk of bleeding "is similar to that observed with aspirin alone." Randomized, double-blind, placebo-controlled study assigned 12,562 patients to either 75 mg/day clopidogrel or placebo, in addition to 75 mg-325 mg aspirin daily
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: